Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18422500 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | January 2024 | September 2025 | Allow | 20 | 1 | 1 | No | No |
| 18479410 | COMBINATION THERAPY USING RIBOCICLIB AND AN AROMATASE INHIBITOR FOR THE TREATMENT OF HR+ BREAST CANCER | October 2023 | December 2025 | Allow | 26 | 4 | 0 | Yes | Yes |
| 18469975 | COMBINATION THERAPY USING RIBOCICLIB AND FULVESTRANT FOR THE TREATMENT OF HR+ BREAST CANCER | September 2023 | December 2025 | Allow | 27 | 4 | 0 | Yes | Yes |
| 18261832 | USE OF PYRIDO[1,2-A]PYRIMIDONE ANALOGUE | July 2023 | March 2026 | Allow | 32 | 1 | 0 | No | No |
| 18126355 | PLEUROMUTILIN DERIVATIVE CONTAINING THIAZOLE-PYRIDINE BENZYL QUATERNARY AMMONIUM SALT SIDE CHAIN AND PREPARATION METHOD AND USE THEREOF | March 2023 | January 2025 | Allow | 22 | 2 | 1 | No | No |
| 18188796 | TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH CAPSINOIDS | March 2023 | February 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18186158 | 3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF | March 2023 | December 2024 | Allow | 21 | 1 | 1 | No | No |
| 18122278 | METHODS OF TREATMENT AND PREVENTION USING 4-DEOXY-L-ERYTHRO-5-HEXOSEULOSE URONIC ACID | March 2023 | March 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18114104 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | February 2023 | March 2025 | Allow | 25 | 1 | 0 | No | No |
| 18114050 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | February 2023 | January 2025 | Allow | 23 | 1 | 0 | No | No |
| 18169423 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | February 2023 | October 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18165776 | HYDROXYSTEROID COMPOUNDS | February 2023 | May 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18160690 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18100412 | SOLID FORMS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18156186 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS | January 2023 | December 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17909179 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | December 2022 | March 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17989956 | SELF-ASSEMBLED COMPLEX CONTAINING COPPER IONS | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17922405 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | October 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17997335 | BCL-2 PROTEIN INHIBITORS | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17996821 | ACYCLIC CUCURBITURILS, METHODS OF MAKING SAME, AND USES THEREOF | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17918497 | PULMONARY FIBROSIS MEDICINE CONTAINING PYRAZOLE DERIVATIVE | October 2022 | February 2026 | Allow | 40 | 2 | 0 | No | No |
| 17914671 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17913976 | MATERIALS AND METHODS FOR IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT-TARGETED CANCER THERAPY | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17622287 | INHIBITORS OF PRC1 FOR TREATMENT OF CANCER | September 2022 | February 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17905847 | OXADIAZOLE DERIVATIVE | September 2022 | January 2026 | Allow | 40 | 2 | 0 | Yes | No |
| 17909709 | AMPHIPHILIC ALGINATE-OLEIC ACID MACROMOLECULES AND PROCESS FOR PREPARATION THEREOF | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17908752 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | September 2022 | September 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17904822 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | August 2022 | April 2025 | Allow | 31 | 1 | 0 | No | No |
| 17866453 | METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA | July 2022 | January 2026 | Allow | 42 | 1 | 0 | Yes | No |
| 17843774 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | June 2022 | January 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17786765 | CRYSTALS OF 3-HYDROXY-N'-(1,3-DIMETHYLBUTYLIDENE)-2-NAPHTHOIC ACID HYDRAZIDE AND PRODUCTION METHOD FOR THE SAME | June 2022 | June 2025 | Allow | 36 | 1 | 0 | No | No |
| 17757511 | COMBINATIONS | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17782870 | SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASES | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17831617 | COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER | June 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17830215 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17780971 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | May 2022 | September 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17777881 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | May 2022 | December 2025 | Allow | 43 | 1 | 0 | No | No |
| 17741989 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | May 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17741206 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17775133 | PAPD5 Inhibition As A Treatment For Dyskeratosis Congenita, Aplastic Anemia And Myelodysplastic Syndrome Caused By Reduced Telomerase RNA Levels | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17773498 | TARGETING P73 FOR CANCERS RESISTANT TO BH3 MIMETICS | April 2022 | March 2026 | Abandon | 47 | 3 | 0 | No | No |
| 17729929 | INHIBITORS OF RAF KINASES | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17771527 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | April 2022 | August 2025 | Allow | 40 | 2 | 1 | No | No |
| 17767408 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | April 2022 | October 2025 | Allow | 43 | 3 | 0 | No | No |
| 17630114 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | April 2022 | November 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17767270 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS | April 2022 | September 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17712001 | METHODS USING HDAC11 INHIBITORS | April 2022 | July 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 16304935 | METHODS FOR TREATING SMARCB1 DEFICIENT CANCER OR PAZOPANIB RESISTANT CANCER | March 2022 | August 2025 | Abandon | 60 | 1 | 0 | No | No |
| 17638398 | HALOGENATED COMPOUNDS, PROCESS AND USES THEREOF | February 2022 | November 2025 | Abandon | 45 | 1 | 0 | Yes | No |
| 17633307 | Combination Therapy For Treatment Of Cancer | February 2022 | January 2026 | Allow | 48 | 2 | 1 | No | No |
| 17592870 | PROGESTERONE ANALOGS AND USES RELATED THERETO | February 2022 | July 2025 | Allow | 41 | 2 | 0 | No | No |
| 17592426 | COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH | February 2022 | September 2025 | Allow | 44 | 4 | 0 | No | Yes |
| 17597939 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | January 2022 | May 2025 | Allow | 39 | 1 | 1 | No | No |
| 17630673 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | January 2022 | August 2025 | Allow | 42 | 1 | 1 | No | No |
| 17628814 | Lacosamide for the Treatment of ADD/ADHD | January 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17579514 | METHODS OF TREATING HYPERCHOLESTEROLEMIA | January 2022 | July 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17577018 | 2'-ISOPROPYL-SPIRO (3,3'-PYRROLIDINE OXINDOLE) LIVER X RECEPTOR REGULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17566371 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17596830 | TYROSINE KINASE INHIBITOR CONJUGATES | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17596721 | SALTS OF A COMPOUND, CRYSTAL FORMS OF THE SALTS AND PREPARATION METHOD AND USE THEREOF | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17596488 | SMARCA DEGRADERS AND USES THEREOF | December 2021 | November 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17258447 | PHARMACEUTICAL COMPOSITION FOR PREVENTING DIABETES AND USE THEREOF | January 2021 | July 2025 | Abandon | 54 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner HASTINGS, ALISON AZAR works in Art Unit 1627 and has examined 7 patent applications in our dataset. With an allowance rate of 14.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner HASTINGS, ALISON AZAR's allowance rate of 14.3% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HASTINGS, ALISON AZAR receive 1.14 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HASTINGS, ALISON AZAR is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +100.0% benefit to allowance rate for applications examined by HASTINGS, ALISON AZAR. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 150.0% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.